Table 1.
Patient characteristics
| Haplo donor | MSD | MUD TCD+ | MUD TCD− | P | |
|---|---|---|---|---|---|
| Number of patients | 132 | 525 | 403 | 378 | |
| Number of centers | 24 | 86 | 45 | 51 | |
| Reporting registry | <.001 | ||||
| CIBMTR | 97 (73) | 353 (67) | 166 (41) | 263 (70) | |
| EBMT | 35 (27) | 172 (33) | 237 (59) | 115 (30) | |
| Patient age, median (range), y | 58 (20-75) | 55 (19-73) | 55 (19-75) | 56 (23-73) | <.001 |
| Patients ≥60 y | 59 (45) | 135 (26) | 121 (30) | 134 (35) | |
| Male sex | 86 (65) | 323 (62) | 259 (64) | 218 (58) | .22 |
| KPS ≥90 | 96 (73) | 325 (62) | 249 (62) | 216 (57) | .003 |
| KPS missing | 5 (4) | 24 (4) | 26 (6) | 10 (2) | |
| HCT-CI | <.001 | ||||
| 0 | 33 (25) | 119 (23) | 54 (13) | 63 (17) | |
| 1-2 | 31 (23) | 112 (21) | 75 (19) | 84 (22) | |
| ≥3 | 36 (27) | 137 (26) | 85 (21) | 125 (33) | |
| Missing* | 33 (25) | 157 (30) | 189 (47) | 106 (28) | |
| Patient race | <.001 | ||||
| White | 91 (69) | 349 (66) | 258 (64) | 282 (75) | |
| African American | 15 (11) | 12 (2) | 2 (<1) | 5 (1) | |
| Other | 2 (2) | 36 (8) | 2 (<1) | 7 (1) | |
| Missing | 24 (18) | 128 (24) | 141 (36) | 84 (22) | |
| Time from diagnosis to transplant, median (range), mo | 22 (<1-173) | 26 (2-386) | 24 (2-340) | 28 (2-299) | .18 |
| Previous auto-HCT | 56 (42) | 288 (55) | 237 (59) | 229 (61) | .002 |
| Remission status at HCT | .72 | ||||
| Complete | 63 (48) | 217 (41) | 179 (44) | 171 (45) | |
| Partial | 45 (34) | 181 (34) | 133 (33) | 133 (35) | |
| Refractory | 23 (17) | 109 (21) | 74 (18) | 64 (17) | |
| Untreated/unknown | 1 (<1) | 18 (4) | 17 (5) | 10 (3) | |
| TBI in conditioning† | 114 (86) | 109 (21) | 30 (7) | 121 (32) | <.001 |
| Graft type | <.001 | ||||
| Bone marrow | 100 (76) | 10 (2) | 30 (7) | 20 (5) | |
| Peripheral blood | 32 (24) | 515 (98) | 373 (93) | 358 (95) | |
| CMV status | |||||
| D+/R− | 11 (8) | 38 (7) | 21 (5) | 31 (8) | <.001 |
| Missing | 64 (49) | 257 (49) | 240 (58) | 120 (31) | |
| D-R sex match | <.001 | ||||
| Female-male | 42 (32) | 139 (26) | 95 (24) | 66 (17) | |
| Other | 90 (68) | 386 (74) | 306 (75) | 311 (82) | |
| Missing | 0 | 2 (<1) | 2 (<1) | 1 (<1) | |
| GVHD prophylaxis | <.001 | ||||
| PTCy | 132 | N/A | N/A | N/A | |
| CNI + MMF ± others | N/A | 191 (36) | 158 (39) | 159 (42) | |
| CNI + MTX ± others | N/A | 236 (45) | 154 (38) | 150 (40) | |
| CNI + others | N/A | 98 (19) | 91 (23) | 69 (18) | |
| Follow-up of survivors, median (range), mo | 49 (12-73) | 48 (2-97) | 49 (3-100) | 39 (4-96) |
Values in parentheses represent percentages if not indicated otherwise.
A/C, anti–thymocyte globulin/alemtuzumab; CMV, cytomegalovirus; D-R, donor-recipient; HCT-CI, hematopoietic cell transplant-comorbidity index; KPS, Karnofsky performance score; MMF, mycophenolate mofetil; MTX, methotrexate; N/A, not applicable; w, with; w/o, without.
*
EBMT does not collect this variable for minimal essential data (MED-A) patients.
†
Details of conditioning regimens are given in supplemental Table 2.